Findings

What do systematic reviews say?

3 questions · 4 findings · 2 reviews · Skin

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

At least 50% decrease in HS Severity Index · participants with hidradenitis suppurativa

Infliximab showed no clear difference in at least 50% decrease in HS Severity Index compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 4.8 [0.6, 38.48]
1 study · 33 participants
Moderate

Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa

Infliximab probably leads to higher physician global assessment compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 4.8 [1.66, 13.9]
1 study · 33 participants
Moderate

Infliximab · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher infliximab compared with placebo (moderate certainty).

2 findings from 1 review

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes only
RR 29.52 [19.94, 43.7]
5 studies · 1651 participants
Moderate
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes only
RR 1.11 [0.59, 2.07]
6 studies · 1678 participants
Moderate